or IV heart failure and an inadequate response to csDMARDs Switching to a non-TNF inhibitor bDMARD or tsDMARD is conditionally recommended over continuation of a TNF inhibitor for patients taking a TNF inhibitor who develop heart failure These recommendations are based on the risk of worsening heart failure observed in randomized clinical trials of TNF inhibitors in patients with NYHA class III or IV heart failure without RA Lymphoproliferative disorder Rituximab is conditionally recommended